ResMed demonstrated strong financial and operational performance in Q2 2025, supported by double-digit growth across key segments and expanding gross margins. The AirSense 11 platform and AirTouch ...

Recovery in Device Sales: ResMed’s increased device sales continue to drive overall revenue growth, reflecting the ongoing combined availability of AirSense 10 and AirSense 11 sleep devices to ...

The analysts noted that ResMed's gross margin remained roughly flat sequentially but improved by 300 basis points year-over-year, attributed to manufacturing and cost improvements. The AirSense 11 has ...

ResMed Inc.’s RMD growth in the second quarter of fiscal 2025 can be attributed to the robust performance of its Mask business. Its Device sales continue to drive overall revenue growth. The company’s ...